Correlation of genetic variability with safety of mumps vaccine Urabe AM9 strain

被引:31
作者
Amexis, G
Fineschi, N
Chumakov, K [1 ]
机构
[1] US FDA, Ctr Biol Evaluat & Res, Rockville, MD 20852 USA
[2] Chiron SpA, Siena, Italy
关键词
nucleotide polymorphism; reversion; neurovirulence; vaccine production; quality control;
D O I
10.1006/viro.2001.1009
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The Urabe AM9 strain of mumps vaccine live is known for its genetic instability and some vaccines derived from this strain were withdrawn from the market due to an excessive number of vaccine-associated parotitis and meningitis cases. To identify the molecular basis of this instability, we determined complete nucleotide sequences of several stocks of the Urabe strain used for vaccine production by different manufacturers and of two clinical Isolates from cases of vaccine-associated meningitis. In contrast to previously published studies relating the Lys(335) --> Glu mutation in the viral HN gene with neurovirulence of mumps virus, we could not confirm any association of this mutation with the safety of mumps vaccine. Each of the three vaccine stocks studied had its own characteristic profile of mutations that was identified by cDNA sequencing and quantitated by mutant analysis by PCR and restriction enzyme cleavage. Determination of the mutational profile of mumps vaccine lots could allow vaccine manufacturers to characterize seed viruses and monitor the consistency of vaccine production to prevent emergence of virulent revertants.
引用
收藏
页码:234 / 241
页数:8
相关论文
共 46 条
  • [1] Nucleotide sequence at position 1081 of the hemagglutinin-neuraminidase gene in the mumps Urabe vaccine strain
    Afzal, MA
    Yates, PJ
    Minor, PD
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1998, 177 (01) : 265 - 266
  • [2] Evaluation of the neurovirulence test for mumps vaccines
    Afzal, MA
    Marsden, SA
    Hull, RM
    Pipkin, PA
    Bentley, ML
    Minor, PD
    [J]. BIOLOGICALS, 1999, 27 (01) : 43 - 49
  • [3] HETEROGENOUS MUMPS VACCINE
    AFZAL, MA
    PICKFORD, AR
    FORSEY, T
    MINOR, PD
    [J]. LANCET, 1992, 340 (8825) : 980 - 981
  • [4] AFZAL MA, 1994, J GEN VIROL, V75, P2139
  • [5] Autret E, 1996, THERAPIE, V51, P681
  • [6] Risk of hospitalization because of aseptic meningitis after measles-mumps-rubella vaccination in one- to two-year-old children: An analysis of the Vaccine Safety Datalink (VSD) Project
    Black, S
    Shinefield, H
    Ray, P
    Lewis, E
    Chen, R
    Glasser, J
    Hadler, S
    Hardy, J
    Rhodes, P
    Swint, E
    Davis, R
    Thompson, R
    Mullooly, J
    Marcy, M
    Vadheim, C
    Ward, J
    Rastogi, S
    Wise, R
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1997, 16 (05) : 500 - 503
  • [7] GENETIC-EVIDENCE FOR VARIANT SELECTION IN THE COURSE OF DILUTE PASSAGING OF MUMPS VACCINE VIRUS
    BORISKIN, YS
    YAMADA, A
    KAPTSOVA, TI
    SKVORTSOVA, OI
    SINITSYNA, OA
    TAKEUCHI, K
    TANABAYASHI, K
    SUGIURA, A
    [J]. RESEARCH IN VIROLOGY, 1992, 143 (04): : 279 - 283
  • [8] MUMPS-VIRUS VARIANTS IN HETEROGENEOUS MUMPS VACCINE
    BORISKIN, YS
    KAPTSOVA, TI
    BOOTH, JC
    [J]. LANCET, 1993, 341 (8840) : 318 - 319
  • [9] The Urabe AM9 mumps vaccine is a mixture of viruses differing at amino acid 335 of the hemagglutinin-neuraminidase gene with one form associated with disease
    Brown, EG
    Dimock, K
    Wright, KE
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1996, 174 (03) : 619 - 622
  • [10] Brown EG, 1998, REV MED VIROL, V8, P129, DOI 10.1002/(SICI)1099-1654(199807/09)8:3&lt